{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:07:37Z","timestamp":1790824057978,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Microbiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The Gram-negative bacterium\n                    <jats:italic>Bordetella pertussis<\/jats:italic>\n                    causes whooping cough (pertussis), a severe respiratory disease, especially in young children, which is resurgent despite high vaccine coverage. The current acellular pertussis vaccine prevents severe disease but does not prevent nasal infection with\n                    <jats:italic>B. pertussis<\/jats:italic>\n                    . This parenterally delivered vaccine induces potent circulating antibody responses but limited respiratory tissue-resident memory T cells and IgA responses. Here we developed a vaccine approach based on respiratory delivery of antibiotic-inactivated\n                    <jats:italic>B. pertussis<\/jats:italic>\n                    (AIBP). Ciprofloxacin-treated\n                    <jats:italic>B. pertussis<\/jats:italic>\n                    potently activated antigen-presenting cells to drive T cell responses. AIBP immunization via aerosol or intranasal administration conferred a high level of protection against lung and nasal infection. The AIBP vaccine induced\n                    <jats:italic>B. pertussis<\/jats:italic>\n                    -specific interleukin (IL)-17-producing CD4 tissue-resident memory T cells that recruited neutrophils to the respiratory tract. Protection was abrogated by depletion of CD4 T cells or neutralization of IL-17 in mice. Unlike a parenterally delivered whole-cell pertussis vaccine, which induced high levels of serum IL-1\u03b2, IL-6, tumour necrosis factor and C-reactive protein, aerosol immunization with the AIBP vaccine did not promote systemic pro-inflammatory responses. We present preclinical evidence of a safe and effective respiratory-delivered vaccine platform for inducing T cell-mediated sterilizing immunity against a respiratory pathogen.\n                  <\/jats:p>","DOI":"10.1038\/s41564-025-02166-6","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T10:02:06Z","timestamp":1762768926000},"page":"3094-3106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Respiratory immunization using antibiotic-inactivated Bordetella pertussis confers T cell-mediated protection against nasal infection in mice"],"prefix":"10.1038","volume":"10","author":[{"given":"Seyed Davoud","family":"Jazayeri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5718-649X","authenticated-orcid":false,"given":"Lisa","family":"Borkner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline E.","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3646-8222","authenticated-orcid":false,"given":"Kingston H. G.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"2166_CR1","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1016\/j.vaccine.2023.05.011","volume":"41","author":"E Kehagia","year":"2023","unstructured":"Kehagia, E., Papakyriakopoulou, P. & Valsami, G. Advances in intranasal vaccine delivery: a promising non-invasive route of immunization. Vaccine 41, 3589\u20133603 (2023).","journal-title":"Vaccine"},{"key":"2166_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101331","volume":"46","author":"S Minozzi","year":"2022","unstructured":"Minozzi, S. et al. Comparative efficacy and safety of vaccines to prevent seasonal influenza: a systematic review and network meta-analysis. EClinicalMedicine 46, 101331 (2022).","journal-title":"EClinicalMedicine"},{"key":"2166_CR3","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S0140-6736(22)02644-7","volume":"401","author":"C Keech","year":"2023","unstructured":"Keech, C. et al. Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus\u2013diphtheria\u2013acellular pertussis vaccine: a randomised, double-blind, phase 2b trial. Lancet 401, 843\u2013855 (2023).","journal-title":"Lancet"},{"key":"2166_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-015-0133-2","volume":"3","author":"Y Tarabichi","year":"2015","unstructured":"Tarabichi, Y. et al. The administration of intranasal live attenuated influenza vaccine induces changes in the nasal microbiota and nasal epithelium gene expression profiles. Microbiome 3, 74 (2015).","journal-title":"Microbiome"},{"key":"2166_CR5","doi-asserted-by":"publisher","first-page":"e6999","DOI":"10.1371\/journal.pone.0006999","volume":"4","author":"DJ Lewis","year":"2009","unstructured":"Lewis, D. J. et al. Transient facial nerve paralysis (Bell\u2019s palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS ONE 4, e6999 (2009).","journal-title":"PLoS ONE"},{"key":"2166_CR6","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/s41590-023-01625-8","volume":"24","author":"KHG Mills","year":"2023","unstructured":"Mills, K. H. G. How immunology can help reverse the pertussis vaccine failure. Nat. Immunol. 24, 1779\u20131780 (2023).","journal-title":"Nat. Immunol."},{"key":"2166_CR7","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1128\/IAI.66.2.594-602.1998","volume":"66","author":"KH Mills","year":"1998","unstructured":"Mills, K. H., Ryan, M., Ryan, E. & Mahon, B. P. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect. Immun. 66, 594\u2013602 (1998).","journal-title":"Infect. Immun."},{"key":"2166_CR8","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1128\/CMR.18.2.326-382.2005","volume":"18","author":"S Mattoo","year":"2005","unstructured":"Mattoo, S. & Cherry, J. D. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin. Microbiol. Rev. 18, 326\u2013382 (2005).","journal-title":"Clin. Microbiol. Rev."},{"key":"2166_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6702a1","volume":"67","author":"JL Liang","year":"2018","unstructured":"Liang, J. L. et al. Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 67, 1\u201344 (2018).","journal-title":"MMWR Recomm. Rep."},{"key":"2166_CR10","doi-asserted-by":"publisher","first-page":"e012945","DOI":"10.1136\/bmjopen-2016-012945","volume":"7","author":"J Patterson","year":"2017","unstructured":"Patterson, J., Kagina, B. M., Gold, M., Hussey, G. D. & Muloiwa, R. Adverse events following primary and secondary immunisation with whole-cell pertussis: a systematic review protocol. BMJ Open 7, e012945 (2017).","journal-title":"BMJ Open"},{"key":"2166_CR11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJM199602083340601","volume":"334","author":"D Greco","year":"1996","unstructured":"Greco, D. et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N. Engl. J. Med. 334, 341\u2013348 (1996).","journal-title":"N. Engl. J. Med."},{"key":"2166_CR12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1056\/NEJM199602083340602","volume":"334","author":"L Gustafsson","year":"1996","unstructured":"Gustafsson, L., Hallander, H. O., Olin, P., Reizenstein, E. & Storsaeter, J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 334, 349\u2013355 (1996).","journal-title":"N. Engl. J. Med."},{"key":"2166_CR13","unstructured":"European Centre for Disease Prevention and Control (ECDC). Pertussis. In Annual Epidemiological Report for 2023. (ECDC, 2025); https:\/\/www.ecdc.europa.eu\/en\/publications-data\/pertussis-annual-epidemiological-report-2023"},{"key":"2166_CR14","doi-asserted-by":"publisher","first-page":"2400459","DOI":"10.2807\/1560-7917.ES.2024.29.31.2400459","volume":"29","author":"C Rodrigues","year":"2024","unstructured":"Rodrigues, C. et al. Resurgence of Bordetella pertussis, including one macrolide-resistant isolate, France, 2024. Euro. Surveill. 29, 2400459 (2024).","journal-title":"Euro. Surveill."},{"key":"2166_CR15","doi-asserted-by":"publisher","first-page":"q2114","DOI":"10.1136\/bmj.q2114","volume":"386","author":"JH Tanne","year":"2024","unstructured":"Tanne, J. H. Whooping cough: fivefold rise in US cases spells return to pre-pandemic levels. BMJ 386, q2114 (2024).","journal-title":"BMJ"},{"key":"2166_CR16","doi-asserted-by":"publisher","first-page":"2400301","DOI":"10.2807\/1560-7917.ES.2024.29.23.2400301","volume":"29","author":"M Poeta","year":"2024","unstructured":"Poeta, M. et al. Pertussis outbreak in neonates and young infants across Italy, January to May 2024: implications for vaccination strategies. Euro. Surveill. 29, 2400301 (2024).","journal-title":"Euro. Surveill."},{"key":"2166_CR17","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1056\/NEJMoa1200850","volume":"367","author":"NP Klein","year":"2012","unstructured":"Klein, N. P., Bartlett, J., Rowhani-Rahbar, A., Fireman, B. & Baxter, R. Waning protection after fifth dose of acellular pertussis vaccine in children. N. Engl. J. Med. 367, 1012\u20131019 (2012).","journal-title":"N. Engl. J. Med."},{"key":"2166_CR18","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/22221751.2018.1564630","volume":"8","author":"MM Wilk","year":"2019","unstructured":"Wilk, M. M. et al. Immunization with whole cell but not acellular pertussis vaccines primes CD4 TRM cells that sustain protective immunity against nasal colonization with Bordetella pertussis. Emerg. Microbes Infect. 8, 169\u2013185 (2019).","journal-title":"Emerg. Microbes Infect."},{"key":"2166_CR19","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1073\/pnas.1314688110","volume":"111","author":"JM Warfel","year":"2014","unstructured":"Warfel, J. M., Zimmerman, L. I. & Merkel, T. J. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc. Natl Acad. Sci. USA 111, 787\u2013792 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2166_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0382-8","volume":"13","author":"BM Althouse","year":"2015","unstructured":"Althouse, B. M. & Scarpino, S. V. Asymptomatic transmission and the resurgence of Bordetella pertussis. BMC Med. 13, 146 (2015).","journal-title":"BMC Med."},{"key":"2166_CR21","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.3389\/fimmu.2018.03068","volume":"9","author":"L Solans","year":"2018","unstructured":"Solans, L. & Locht, C. The role of mucosal immunity in pertussis. Front. Immunol. 9, 3068 (2018).","journal-title":"Front. Immunol."},{"key":"2166_CR22","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41385-021-00407-5","volume":"14","author":"L Borkner","year":"2021","unstructured":"Borkner, L., Curham, L. M., Wilk, M. M., Moran, B. & Mills, K. H. G. IL-17 mediates protective immunity against nasal infection with Bordetella pertussis by mobilizing neutrophils, especially Siglec-F+ neutrophils. Mucosal Immunol. 14, 1183\u20131202 (2021).","journal-title":"Mucosal Immunol."},{"key":"2166_CR23","doi-asserted-by":"publisher","first-page":"e1003264","DOI":"10.1371\/journal.ppat.1003264","volume":"9","author":"PJ Ross","year":"2013","unstructured":"Ross, P. J. et al. Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine. PLoS Pathog. 9, e1003264 (2013).","journal-title":"PLoS Pathog."},{"key":"2166_CR24","doi-asserted-by":"publisher","first-page":"e0089221","DOI":"10.1128\/msphere.00892-21","volume":"7","author":"MC Gestal","year":"2022","unstructured":"Gestal, M. C., Howard, L. K., Dewan, K. K. & Harvill, E. T. Bbvac: a live vaccine candidate that provides long-lasting anamnestic and Th17-mediated immunity against the three classical Bordetella spp. mSphere 7, e0089221 (2022).","journal-title":"mSphere"},{"key":"2166_CR25","doi-asserted-by":"publisher","first-page":"e518","DOI":"10.1093\/infdis\/jiae034","volume":"230","author":"KN McCarthy","year":"2024","unstructured":"McCarthy, K. N., Hone, S., McLoughlin, R. M. & Mills, K. H. G. IL-17 and IFN-\u03b3-producing respiratory tissue-resident memory CD4 T cells persist for decades in adults immunized as children with whole-cell pertussis vaccines. J. Infect. Dis. 230, e518\u2013e523 (2024).","journal-title":"J. Infect. Dis."},{"key":"2166_CR26","first-page":"377","volume":"61","author":"K Drlica","year":"1997","unstructured":"Drlica, K. & Zhao, X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61, 377\u2013392 (1997).","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"2166_CR27","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1128\/iai.61.8.3190-3198.1993","volume":"61","author":"K Redhead","year":"1993","unstructured":"Redhead, K., Watkins, J., Barnard, A. & Mills, K. H. Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity. Infect. Immun. 61, 3190\u20133198 (1993).","journal-title":"Infect. Immun."},{"key":"2166_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00270-8","volume":"6","author":"V Dubois","year":"2021","unstructured":"Dubois, V. et al. Suppression of mucosal Th17 memory responses by acellular pertussis vaccines enhances nasal Bordetella pertussis carriage. NPJ Vaccines 6, 6 (2021).","journal-title":"NPJ Vaccines"},{"key":"2166_CR29","doi-asserted-by":"publisher","first-page":"e1000647","DOI":"10.1371\/journal.ppat.1000647","volume":"5","author":"HJ Wearing","year":"2009","unstructured":"Wearing, H. J. & Rohani, P. Estimating the duration of pertussis immunity using epidemiological signatures. PLoS Pathog. 5, e1000647 (2009).","journal-title":"PLoS Pathog."},{"key":"2166_CR30","doi-asserted-by":"publisher","first-page":"S310","DOI":"10.1093\/infdis\/jiaa469","volume":"224","author":"MD Decker","year":"2021","unstructured":"Decker, M. D. & Edwards, K. M. Pertussis (whooping cough). J. Infect. Dis. 224, S310\u2013S320 (2021).","journal-title":"J. Infect. Dis."},{"key":"2166_CR31","doi-asserted-by":"publisher","first-page":"1210580","DOI":"10.3389\/fimmu.2023.1210580","volume":"14","author":"M Callender","year":"2023","unstructured":"Callender, M. & Harvill, E. T. Maternal vaccination: shaping the neonatal response to pertussis. Front. Immunol. 14, 1210580 (2023).","journal-title":"Front. Immunol."},{"key":"2166_CR32","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1097\/01.inf.0000160915.93979.8f","volume":"24","author":"A Van Rie","year":"2005","unstructured":"Van Rie, A., Wendelboe, A. M. & Englund, J. A. Role of maternal pertussis antibodies in infants. Pediatr. Infect. Dis. J. 24, S62\u2013S65 (2005).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"2166_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1387534","volume":"15","author":"B Pschunder","year":"2024","unstructured":"Pschunder, B. et al. Outer membrane vesicles derived from Bordetella pertussis are potent adjuvant that drive Th1-biased response. Front. Immunol. 15, 1387534 (2024).","journal-title":"Front. Immunol."},{"key":"2166_CR34","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1038\/s41385-018-0080-x","volume":"11","author":"AC Allen","year":"2018","unstructured":"Allen, A. C. et al. Sustained protective immunity against Bordetella pertussis nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting TRM cells. Mucosal Immunol. 11, 1763\u20131776 (2018).","journal-title":"Mucosal Immunol."},{"key":"2166_CR35","first-page":"e00607","volume":"89","author":"MA Wolf","year":"2021","unstructured":"Wolf, M. A. et al. Intranasal immunization with acellular pertussis vaccines results in long-term immunity to Bordetella pertussis in mice. Infect. Immun. 89, e00607\u2013e00620 (2021).","journal-title":"Infect. Immun."},{"key":"2166_CR36","doi-asserted-by":"publisher","first-page":"e83449","DOI":"10.1371\/journal.pone.0083449","volume":"9","author":"R Thorstensson","year":"2014","unstructured":"Thorstensson, R. et al. A phase I clinical study of a live attenuated Bordetella pertussis vaccine\u2014BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers. PLoS ONE 9, e83449 (2014).","journal-title":"PLoS ONE"},{"key":"2166_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-68248-z","volume":"10","author":"TJM Michiels","year":"2020","unstructured":"Michiels, T. J. M., Meiring, H. D., Jiskoot, W., Kersten, G. F. A. & Metz, B. Formaldehyde treatment of proteins enhances proteolytic degradation by the endo-lysosomal protease cathepsin S. Sci. Rep. 10, 11535 (2020).","journal-title":"Sci. Rep."},{"key":"2166_CR38","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/0167-5699(86)90006-X","volume":"7","author":"KH Mills","year":"1986","unstructured":"Mills, K. H. Processing of viral antigens and presentation to class II-restricted T cells. Immunol. Today 7, 260\u2013263 (1986).","journal-title":"Immunol. Today"},{"key":"2166_CR39","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ejmech.2018.01.078","volume":"146","author":"GF Zhang","year":"2018","unstructured":"Zhang, G. F., Liu, X., Zhang, S., Pan, B. & Liu, M. L. Ciprofloxacin derivatives and their antibacterial activities. Eur. J. Med. Chem. 146, 599\u2013612 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"2166_CR40","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.1128\/IAI.69.7.4217-4223.2001","volume":"69","author":"S Donnelly","year":"2001","unstructured":"Donnelly, S., Loscher, C. E., Lynch, M. A. & Mills, K. H. Whole-cell but not acellular pertussis vaccines induce convulsive activity in mice: evidence of a role for toxin-induced interleukin-1\u03b2 in a new murine model for analysis of neuronal side effects of vaccination. Infect. Immun. 69, 4217\u20134223 (2001).","journal-title":"Infect. Immun."},{"key":"2166_CR41","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4161\/hv.22847","volume":"9","author":"WO Dias","year":"2013","unstructured":"Dias, W. O. et al. An improved whole cell pertussis vaccine with reduced content of endotoxin. Hum. Vaccin. Immunother. 9, 339\u2013348 (2013).","journal-title":"Hum. Vaccin. Immunother."},{"key":"2166_CR42","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.3389\/fimmu.2018.01764","volume":"9","author":"L Borkner","year":"2018","unstructured":"Borkner, L., Misiak, A., Wilk, M. M. & Mills, K. H. G. Azithromycin clears Bordetella pertussis infection in mice but also modulates innate and adaptive immune responses and T cell memory. Front. Immunol. 9, 1764 (2018).","journal-title":"Front. Immunol."},{"key":"2166_CR43","doi-asserted-by":"publisher","first-page":"111548","DOI":"10.1016\/j.isci.2024.111548","volume":"28","author":"E O\u2019Neill","year":"2025","unstructured":"O\u2019Neill, E. et al. Neonatal infection with Bordetella pertussis promotes autism-like phenotypes in mice. iScience 28, 111548 (2025).","journal-title":"iScience"},{"key":"2166_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2022.101664","volume":"3","author":"M Sauter","year":"2022","unstructured":"Sauter, M. et al. Protocol to isolate and analyze mouse bone marrow derived dendritic cells (BMDC). STAR Protoc. 3, 101664 (2022).","journal-title":"STAR Protoc."}],"updated-by":[{"DOI":"10.1038\/s41564-025-02243-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000}}],"container-title":["Nature Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41564-025-02166-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-025-02166-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-025-02166-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:02:08Z","timestamp":1765958528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41564-025-02166-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":44,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2166"],"URL":"https:\/\/doi.org\/10.1038\/s41564-025-02166-6","relation":{},"ISSN":["2058-5276"],"issn-type":[{"value":"2058-5276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41564-025-02243-w","URL":"https:\/\/doi.org\/10.1038\/s41564-025-02243-w","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.H.G.M. and S.D.J. are inventors on a patent application (PCT\/EP2025\/065749) on the AIBP vaccine. K.H.G.M. is an inventor on a patent (US Patent Application Number 16\/271802) around an adjuvant for a pertussis vaccine and has received research funding and acted as a consultant for vaccine manufacturers. L.B. and C.E.S. do not have any competing interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}